Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

News | Stents

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

Home April 06, 2021
Home
Videos | Coronavirus (COVID-19)

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

Home April 01, 2021
Home
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.
Feature | Coronavirus (COVID-19)

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

Home December 23, 2020
Home
News | Cath Lab

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

Home November 16, 2020
Home
The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
News | Atrial Fibrillation

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

Home October 17, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Stents

October 1, 2020 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual ...

Home October 01, 2020
Home
News | Coronavirus (COVID-19)

September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials ...

Home September 11, 2020
Home
Subscribe Now